Amylyx stock price target raised to $16 from $14 at BofA Securities
PositiveFinancial Markets

Amylyx Pharmaceuticals has received a boost as BofA Securities has raised its stock price target from $14 to $16. This adjustment reflects growing confidence in the company's potential and could attract more investors. The increase in the target price is significant as it indicates a positive outlook for Amylyx, especially in the context of its ongoing developments in the pharmaceutical sector.
— Curated by the World Pulse Now AI Editorial System